Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals to $270 from $151 and keeps a Buy rating on the shares. The analyst raised his target based on the positive data reported on Monday from the pivotal trial of resmetirom in NASH. He updated his model and increased his target as the company stated that it is on track to file an NDA with the FDA as early in 1H23 as possible.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Meet the Biotech Stock That Jumped Over 260% in One Day
- Madrigal Pharmaceuticals price target raised to $250 from $170 at Oppenheimer
- Madrigal Pharmaceuticals price target raised to $312 from $182 at JMP Securities
- Raymond James upgrades Madrigal to Market Perform after NASH data
- Madrigal Pharmaceuticals upgraded to Market Perform at Raymond James
